MRCGP AKT → Therapeutics and safe prescribing
Therapeutics and safe prescribing accounts for roughly 1.5% of the MRCGP AKT blueprint. This bank has 26 items tagged to it.
Around 1.5% of the paper, per RCGP GP curriculum (2025). That weighting is why the DocPasser mock builder samples sections in proportion rather than shuffling everything into one pile — practising a flat distribution trains you for a paper that does not exist.
An 82-year-old woman who lives alone takes 11 regular medicines. She has fallen twice in three months. Her medicines include amitriptyline 25 mg at night for nerve pain, oxybutynin for urinary urgency, and bisoprolol. Which single action is most likely to reduce her risk of falling?
The point: Falls with many medicines: look first at anticholinergic drugs, sedatives and anything causing postural hypotension. A structured medication review is a real treatment, not paperwork.
Source: NICE NG249: Falls: assessment and prevention in older people and in people 50 and over at higher risk NICE · tier 1, national regulator or guidance
A 62-year-old man has newly diagnosed hypertension. He started lisinopril 10 mg daily 10 days ago. He takes no other medicines and no over-the-counter tablets. He is eating and drinking normally and has had no vomiting or diarrhoea. Before starting: creatinine 90 micromol/L (60 to 110), potassium 4.6 mmol/L (3.5 to 5.3). Now: creatinine 125 micromol/L, potassium 5.1 mmol/L. According to current national guidance, which is the most appropriate next step?
The point: Check urea and electrolytes before starting an ACE inhibitor or ARB, and again 1 to 2 weeks after starting and after each dose rise. Do not change the dose if creatinine rises by less than 30% or eGFR falls by less than 25%. If the change is larger, look for a cause such as dehydration or an NSAID. If there is none, stop the drug or return to the last tolerated dose. Stop for potassium of 6.0 mmol/L or more once other causes are dealt with.
Source: NICE NG203: Chronic kidney disease: assessment and management NICE · tier 1, national regulator or guidance
A 41-year-old woman has bipolar disorder. She has taken modified-release lithium carbonate 800 mg every morning for three years. Her earlier levels were between 0.6 and 0.8 mmol/L. She took her tablets at 8 am today and had her blood test at 10 am. The lithium level is 1.4 mmol/L. She feels well, with no tremor, vomiting, diarrhoea or drowsiness. Her medicines have not changed. Which is the most appropriate next step?
The point: Take lithium samples 12 hours after the last dose. Many people take the tablets at night and have blood taken the next morning. NICE aims for 0.6 to 0.8 mmol/L in people taking lithium for the first time, and 0.8 to 1.0 mmol/L after a relapse on the lower range. Measure levels every 3 months in the first year, then every 6 months, or every 3 months in higher-risk groups. Check urea, electrolytes, calcium, eGFR and thyroid function every 6 months.
Source: BNF: Lithium carbonate British National Formulary · tier 3, national formulary
Cardiovascular health · Metabolic problems and endocrinology · Gastroenterology and nutrition · Children and young people · Mental health, alcohol and substance misuse · Women's health: gynaecology, pregnancy, contraception and breast · Respiratory health · Dermatology · Ear, nose and throat, speech and hearing · Musculoskeletal health · Neurology · Eyes and vision · Renal and urology · Men's health · Haematology · Allergy and clinical immunology · Infectious diseases, travel and sexual health · People at the end of life · Organisation, management and administration · Evidence-based practice and data interpretation